1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Meet Abliva live: Fireside Chat in Lund and Stockholm

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and investors to an informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Lund (20 June) and Stockholm (21 June).

In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Lund or Stockholm during the Midsummer week to hear an update on the company, learn more about the ongoing rights issue, and ask your most pressing questions.

The event is free of charge, and wine and snacks will be served. As seats are limited, please respond quickly to reserve your space.

Lund, 20 June, 16:00 – 18:00 p.m. CEST:
Restaurant Inspira, Medicon Village, Scheeletorget 1.

Stockholm, 21 June, 16:00 – 18:00 p.m. CEST:
Erik Penser Bank, Apelbergsgatan 27.

Please respond to anmalan@abliva.com to reserve your space.

Watch the interview with CEO Ellen Donnelly by #InvestTalks, June 13, 2022: https://youtu.be/CT8cL1LVF1w.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Meet Abliva live: Fireside Chat in Lund and Stockholm

Datum 2022-06-14, kl 17:00
Källa MFN
Bifogade filer
Meet Abliva live: Fireside Chat in Lund and Stockholm